Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2024 07:00 ET | Source: CervoMed Inc.

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data expected...
November 08, 2024 09:55 ET | Source: CervoMed Inc.

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to...
November 07, 2024 08:30 ET | Source: CervoMed Inc.

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the...
November 04, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity...
October 29, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC...
October 15, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

• On track to report topline data from the Phase 2b trial in December 2024 • Neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients • 96% of...
October 02, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that Dr. John...
September 26, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will...
August 27, 2024 08:30 ET | Source: CervoMed Inc.

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the...
August 22, 2024 08:00 ET | Source: CervoMed Inc.

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its recent...